Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.43 |
| ▸ | TNF | P01375 | 3/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187616 | 0.92 | ABL1 (0.36) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL470228 | 0.89 | PIK3CD (0.46) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL470063 | 0.87 | PIK3CD (0.54) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL13190540 | 0.87 | PIK3CA (0.42) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL461308 | 0.86 | PIK3CD (0.42) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL470162 | 0.82 | PIK3CA (0.40) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL459270 | 0.81 | PIK3CD (0.60) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 | |
| SCHEMBL10280411 | 0.79 | PIK3CG (0.42) | PIK3CG | |
| SCHEMBL715801 | 0.79 | PIK3CG (0.42) | PIK3CG | |
| SCHEMBL470331 | 0.79 | PIK3CD (0.47) | PIK3CAPIK3CDPIK3CGPIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2406255-B1 | 4-OXADIAZOL-2-YL-INDAZOLES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2015-04-29 | — | — | EP | disclosed |
| US-8524751-B2 | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases | GlaxoSmithKline Intellecutual Property Development (GB) | 2013-09-03 | — | — | US | disclosed |
| US-8524751-B2 | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases | GlaxoSmithKline Intellecutual Property Development (GB) | 2013-09-03 | — | — | US | disclosed |
| EP-2613781-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2406255-A1 | 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES | Glaxo Group Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010102958-A1 | 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CA 2691/4885PIK3CD 2938/4885PIK3CG 2718/4885 |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | CDK3, CDK13, AKT3 | PIK3CA 6/4885PIK3CD 11/4885PIK3CG 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.